Romidepsin (FK228, Depsipeptide)

Catalog No.S3020 Synonyms: FR 901228, NSC 630176

Romidepsin (FK228, Depsipeptide) Chemical Structure

Molecular Weight(MW): 540.7

Romidepsin (FK228, depsipeptide) is a potent HDAC1 and HDAC2 inhibitor with IC50 of 36 nM and 47 nM in cell-free assays, respectively.

Size Price Stock Quantity  
USD 157 In stock
USD 477 In stock
USD 697 In stock

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

3 Customer Reviews

  • An HIV-Gag-SLYNTVATL-specific CTL clone was labeled with Alexa-Fluor555 conjugated cholera toxin subunit B either cultured with 500 nM SAHA or 25 nM romidepsin for 20 hours, or maintained as an untreated control. These effector cells were combined with SLYNTVATL peptide pulsed target cells, matched on the restricting allele, in a collagen matrix medium containing sytox green viability dye. These mixtures were then plated in three separate wells of an 8-well cover slip and imaged by time-lapse brightfield and fluorescent microscopy. A. Shown are representative fields of view from the no treatment (upper panel), 500 nM SAHA (middle panel), and 25 nM romidepsin (lower panel) conditions advancing in time from left to right. Time stamps are given in hh[ratio]mm format. Clones described in the results are indicated with yellow arrows and killed target cells are indicated with white arrows in the upper right panel.

    PLoS Pathog 2014 10(8), e1004287. Romidepsin (FK228, Depsipeptide) purchased from Selleck.

    PLZF-RARa–nonexpressing and -expressing PLZFRARβ3 cells were treated with 5 nmol/L romidepsin for the indicated time points. Induction of the DNA DSB marker γH2AX was measured by Western blotting. β-Actin was used as a loading control.

    Mol Cancer Ther 2013 12(8), 1591-604. Romidepsin (FK228, Depsipeptide) purchased from Selleck.

  • Effects of combination of bort/romidepsin on HDAC6 inhibition and activation of ER stress signaling. HA cells were treated with combination of 15 nM bortezomib and 5 nM romidepsin or either drug alone for 24 hr. Expression of CHOP/GADD153 (green signals) and cleaved PARP (red signals) was detected by immunofluorescent staining. DAPI (blue signals) stained the cell nuclei.

    Int J Cancer 2014 135(12):2950-61. Romidepsin (FK228, Depsipeptide) purchased from Selleck.

Purity & Quality Control

Choose Selective HDAC Inhibitors

Biological Activity

Description Romidepsin (FK228, depsipeptide) is a potent HDAC1 and HDAC2 inhibitor with IC50 of 36 nM and 47 nM in cell-free assays, respectively.
Features More effective than other classical HDAC inhibitors such as TSA, TPX, and butyrate.
Targets
HDAC1 [1]
(Cell-free assay)
HDAC2 [1]
(Cell-free assay)
36 nM 47 nM
In vitro

Unlike TSA, the active form redFK of Romidepsin strongly inhibits HDAC1 and HDAC2 with IC50 of 1.6 nM and 3.9 nM, respectively, but is relatively weak in inhibiting HDAC4 and HDAC6 with IC50 25 nM and 790 nM, respectively. Romidepsin is 17-23 times weaker than redFK in inhibiting these HDACs with IC50 of 36 nM, 47 nM, 510 nM, and 14 μM, respectively. Romidepsin treatment in HeLa cells induces histone acetylation and p21 expression with EC50 of 3.0 nM, more strongly than redFK with EC50 of 11 nM due to the instability of redFK. [1] In addition to G2/M arrest, Romidepsin treatment causes cyclin D1 downregulation and a p53-independent p21 induction, leading to inhibition of CDK and dephosphorylation of Rb resulting in growth arrest in the early G1 phase. [2] Romidepsin is 100 times more potent than TSA and 1,000,000 times more potent than butyrate in inhibiting the proliferation of the A549 cells. [3] Romidepsin inhibits the growth of U-937, K562, and CCRF-CEM cells with IC50 of 5.92 nM, 8.36 nM, and 6.95 nM, respectively. [5] Romidepsin promotes apoptosis in chronic lymphocytic leukemia (CLL) cells at a concentration corresponding to that at which H3 and H4 acetylation and HDAC inhibition occurs, selectively involving activation of caspase 8 and effector caspase 3, as well as down-regulation of c-FLIP protein. [6] In 11 of 13 (85%) renal cell carcinoma cell lines and in 16 of 37 (43%) other cancer cell lines, Romidepsin treatment up-regulates tumor death receptors, and potentiates natural killer (NK)-mediated tumor killing. [7] Romidepsin exhibits concentration-dependent cytotoxicity against a panel of mantle cell lymphoma (MCL) cell lines. [9]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
SU-DHL4 M3zoVGNmdGxiVnnhZoltcXS7IFHzd4F6 MmfUNk42NTF3IH7N NX[zbXJsPzJiaB?= NY\LUo1zcW6mdXPld{BkgXSxdH;4bYNqfHliaX6gZUBkd26lZX70doF1cW:wLXTldIVv\GWwdDDtZY5v\XMEoB?= NGPSdmczPTd7MEmwOy=>
U2932  MlexR4VtdCCYaXHibYxqfHliQYPzZZk> M3;nPFIvPS1zNTDuUS=> MX:3NkBp MULpcoR2[2W|IHP5eI91d3irY3n0fUBqdiCjIHPvcoNmdnS{YYTpc44u\GWyZX7k[Y51KG2jbn7lduKh MXOyOVc6ODlyNx?=
OCI-LY7 NHLVT5ZE\WyuIG\pZYJqdGm2eTDBd5NigQ>? MmDXNk42NTF3IH7N MkLOO|IhcA>? NVXxfZB{cW6mdXPld{BkgXSxdH;4bYNqfHliaX6gZUBkd26lZX70doF1cW:wLXTldIVv\GWwdDDtZY5v\XMEoB?= NFfXbWYzPTd7MEmwOy=>
Farage M2jBfWNmdGxiVnnhZoltcXS7IFHzd4F6 NXrSOlBEOi53LUG1JI5O MmHqO|IhcA>? NVTtcYhycW6mdXPld{BkgXSxdH;4bYNqfHliaX6gZUBkd26lZX70doF1cW:wLXTldIVv\GWwdDDtZY5v\XMEoB?= MnTqNlU4QTB7MEe=
LY7/EBV NEDwTXJE\WyuIG\pZYJqdGm2eTDBd5NigQ>? MYWyMlUuOTVibl2= Mn6xO|IhcA>? M1y3cIlv\HWlZYOgZ5l1d3SxeHnjbZR6KGmwIHGgZ49v[2WwdILheIlwdi2mZYDlcoRmdnRibXHucoVzyqB? M4\Pc|I2PzlyOUC3
U2932/EBV M2eyd2NmdGxiVnnhZoltcXS7IFHzd4F6 NIPo[4MzNjVvMUWgcm0> NEn2UWI4OiCq NWW4NWdDcW6mdXPld{BkgXSxdH;4bYNqfHliaX6gZUBkd26lZX70doF1cW:wLXTldIVv\GWwdDDtZY5v\XMEoB?= NYOwVGNzOjV5OUC5NFc>
HCT116 MlqyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{jXWVUuPTByMDDuUS=> MoH6NlQhcA>? M3HqUWROW09? NFW2ZYdqdmS3Y3XzJINmdGxiZHXheIghcW5iYTDjc45k\W62cnH0bY9vNWSncHXu[IVvfCCvYX7u[ZI> MYKyOVQ6OjVzNR?=
ACH-2 M4jUSmZ2dmO2aX;uJGF{e2G7 Mm\rNU06KG6P M3TNbFI1KGh? NHixR5BqdmS3Y3XzJGhKXi1zIFXuekBmgHC{ZYPzbY9v NIDPTnczPTF2OUS2Oy=>
MCF-10A MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX7JR|UxRTBwMUhCtVAvODFibl2= MXyyOFk2PDh3Nh?=
MCF-7 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWWxeJM6UUN3ME2xMlExyrFyLkKwJI5O MVyyOFk2PDh3Nh?=
SK-BR-3 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1\hc2lEPTB;MT6wNOKyOC5|NTDuUS=> MmDlNlQ6PTR6NU[=
MDA-MB-231 NF;UfIhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkK4TWM2OD1yLk[4xtExNjF2IH7N M4Wwd|I1QTV2OEW2
PC3 NUPGWndlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlixTWM2OD1zLk[1xtExNjN3IH7N MkTYNlQ6PTR6NU[=
HCT116 NWe0RYNYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYfLflZEUUN3ME2xMlAxyrFyLkCwJI5O NHnZdGIzPDl3NEi1Oi=>
HCT116-p21-/- Moq3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MknvTWM2OD1zLkK2xtExNjN5IH7N NX20WnE3OjR7NUS4OVY>
S1 NEG3dIpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXXUOHZCUUN3ME23MlY4yrFyLkK5JI5O MlzVNlQ6PTR6NU[=
SW620 NFHQZldIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFrrd5FKSzVyPUCuPVPDuTBwMkmgcm0> MkPRNlQ6PTR6NU[=
LOX-IMVI M4LS[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYDJR|UxRTBwOEhCtVAvODNibl2= MoDDNlQ6PTR6NU[=
UACC-62 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3fyUGlEPTB;MD61OuKyOC5zNjDuUS=> M2HKTFI1QTV2OEW2
MDA-MB-435 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MojFTWM2OD1yLkmwxtExNjB4IH7N MknNNlQ6PTR6NU[=
SF-295 NYXHWI15T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1zPbWlEPTB;MD64POKyOC5zNTDuUS=> NF\GNlMzPDl3NEi1Oi=>
A549 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX3JR|UxRTFwMkdCtVAvOjRibl2= MViyOFk2PDh3Nh?=
H460 NUnlSVVOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmH2TWM2OD1{LkW4xtExNjhyIH7N MnqzNlQ6PTR6NU[=
EKVX MlrsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4ewbmlEPTB;MT6zN:KyOC5|NDDuUS=> NUHZUpdDOjR7NUS4OVY>
H146 M1v4[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoDHTWM2OD1yLkKyxtExNjB5IH7N MWGyOFk2PDh3Nh?=
H526 M17Remdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX\3U5BtUUN3ME2wMlE2yrFyLkCzJI5O NHHlWo8zPDl3NEi1Oi=>
HuT-78 NV;iSmJNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIDGcFZKSzVyPUGuO|PDuTBwNESgcm0> NWfyOm5MOjR7NUS4OVY>
HA Ml;TS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVnmbm9nOC54MkWtNVBvVQ>? NGSz[JE1QCCq NEmzfWNqdmS3Y3XzJIEhe2mpbnnmbYNidnSueTDzeJJwdmencjDpcohq[mm2aX;uJI9nKGOnbHygdJJwdGmoZYLheIlwdiClbz30doVifGWmIIfpeIgh[m:{dHX6c41q[g>? NHXLVHMzPDd5MUWxNC=>
MS-275 NIT4WoxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2P1[|AvPjJ3LUGwcm0> MVG0PEBp MVrpcoR2[2W|IHGgd4lodmmoaXPhcpRtgSC|dILvcodmeiCrbnjpZol1cW:wIH;mJINmdGxicILvcIln\XKjdHnvckBkdy22cnXheIVlKHerdHigZo9zfGW8b33pZi=> NWjVSm5HOjR5N{G1NVA>
CD4 T MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVPIV3Z7PDhiaB?= MWrFR|UxRTRwNdMxNU4xKG6P MlfLNlQ4OjJ2NUS=
CD4 T NVfHdG9uT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUi0PEBp NEfVUo1ESzVyPUGwO:KyOTJ4IH7N NUTGWo5vOjR5MkK0OVQ>
CD4+ T M1T2b2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MW\FR|UxRTNibl2= MUeyOFQ6PTFyNR?=
A549 NV\1Z4hCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2HsUlEx6oDVMUCwxsBvVQ>? NGP5NYQzPC9|Nj:0PEBp M33BT4lvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHLveIgh[2:wY3XueJJifGmxbj2gZY5lKHSrbXWt[IVx\W6mZX70JI1idm6nch?= M1uyTlI1PDh3N{m5
JJN3 M4HITGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVX5VGIyOjRxNEigbC=> NFfReZNGSzVyPEJihKlvVTtiNElihKlp MnLFNlQxOzBzNUC=
OPM-2 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH\LTGYzPC92ODDo NHvheIpGSzVyc{2x5qCKdk19IES45qCKcA>? M37HNFI1ODNyMUWw
RPMI-8226 M4\ST2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFzUe4UzPC92ODDo NVLN[2ZUTUN3MIO9NU456oDLbl27JFQ56oDLaB?= MVKyOFA{ODF3MB?=
U266 M{WxR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEf4VHgzPC92ODDo NIjxU4JGSzVyc{2xNQKBkW6POzC0PQKBkWh? NH\3OXUzPDB|MEG1NC=>
CA46 MYLBdI9xfG:|aYOgRZN{[Xl? M2fuN|YhcA>? MUjpcoR2[2W|IHLseY51KGGyb4D0c5Nqew>? MWGyN|k3PjF4NB?=
DG75 NYj4NnBuSXCxcITvd4l{KEG|c3H5 NHPBfGY3KGh? Mk\ZbY5lfWOnczDuc{BieG:ydH;zbZM> NEHyVHUzOzl4NkG2OC=>
Ramos Mmj0RZBweHSxc3nzJGF{e2G7 NWCwbo96PiCq M2jRZYlv\HWlZYOg[Zh1\W6|aY\lJIFxd3C2b4Ppdy=> NVTv[3RJOjN7Nk[xOlQ>
ST486 MnfDRZBweHSxc3nzJGF{e2G7 M1\O[FYhcA>? NI\2W5JqdmS3Y3XzJIV5fGWwc3n2[UBieG:ydH;zbZM> M3jNcFI{QTZ4MU[0
HuT78 MVnBdI9xfG:|aYOgRZN{[Xl? NE\iO2syNzFyL{GwNEBvVQ>? MoDVOFghcA>? NHy1cmdqdmS3Y3XzJIFxd3C2b4Ppd{BifCBzIH7N NYjzS|N7OjN3M{K3N|I>
DpVp35 MXfBdI9xfG:|aYOgRZN{[Xl? NUTXOFBQOS9zMD:xNFAhdk1? NH\2clU1QCCq NHzs[pdqdmS3Y3XzJIJtfW62IHHwc5B1d3Orcx?= MXWyN|U{Ojd|Mh?=
DpVp50 MkHiRZBweHSxc3nzJGF{e2G7 M1TQNFEwOTBxMUCwJI5O NWXEdIM3PDhiaB?= NXPh[XVycW6mdXPld{BjdHWwdDDhdI9xfG:|aYO= MV2yN|U{Ojd|Mh?=
DpP75  NVi2emE{SXCxcITvd4l{KEG|c3H5 M4WwcVEwOTBxMUCwJI5O MlHuOFghcA>? M2\CVIlv\HWlZYOgZox2dnRiYYDvdJRwe2m| MU[yN|U{Ojd|Mh?=
SKOV-3 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVex5qCUOjCwTR?= NYLoVpI2PzJiaB?= MljpSG1UVw>? NGLqeo1z\WS3Y3XzJINmdGxidnnhZoltcXS7IHHsc45mKGGwZDDjc41jcW6nZDD3bZRpKGOrc4DsZZRqdg>? MYGyN|AyODN2OB?=
Brca1 WT Mme5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIPRdZQy6oDVMkDuUS=> MlrzO|IhcA>? NV3iR|FjTE2VTx?= NHHRdFBz\WS3Y3XzJINmdGxidnnhZoltcXS7IHHsc45mKGGwZDDjc41jcW6nZDD3bZRpKGOrc4DsZZRqdg>? NI\OSHgzOzBzMEO0PC=>
Brca1 Null NEXoXFdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NULR[JpKOeLCk{Kwcm0> MVy3NkBp NVXrcW1jTE2VTx?= MmTRdoVlfWOnczDj[YxtKH[rYXLpcIl1gSCjbH;u[UBidmRiY3;tZolv\WRid3n0bEBkcXOybHH0bY4> NHfkVnUzOzBzMEO0PC=>
OVCAR-8  MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHPmRowy6oDVMkDuUS=> Mom4O|IhcA>? MV3EUXNQ M3j5WJJm\HWlZYOgZ4VtdCC4aXHibYxqfHliYXzvcoUh[W6mIHPvcYJqdmWmIIfpeIgh[2m|cHzheIlv MVWyN|AyODN2OB?=
NCI/ADR-RES MnHKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYKx5qCUOjCwTR?= NGm2[Gw4OiCq NV\Be4hLTE2VTx?= MUfy[YR2[2W|IHPlcIwhfmmjYnnsbZR6KGGub37lJIFv\CClb33ibY5m\CC5aYToJINqe3CuYYTpci=> MlW1NlMxOTB|NEi=
HCT116 NWDFNlZ[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX7hS25CPSCwTT21NEDPxE1? M1e2T|I1KGh? MWnEUXNQ M4nZSIlvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGgZ49v[2WwdILheIlwdi2mZYDlcoRmdnRibXHucoVz MljaNlI6OjR7NUi=
RKO M{HLZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUC1JI5ONTVyIN88US=> MWeyOEBp NHrDPYJFVVOR NF7kO5ZqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJINwdmOnboTyZZRqd25vZHXw[Y5l\W62IH3hco5meg>? NXLiSYNtOjJ7MkS5OVg>
CO115 NVywOIJDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVH0dHl[PSCwTT21NEDPxE1? MnK0NlQhcA>? NGTpeVhFVVOR MULpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHPvcoNmdnS{YYTpc44u\GWyZX7k[Y51KG2jbn7ldi=> MUOyNlkzPDl3OB?=
HFS MnfRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVW1JI5O MVGyOE81QC95MjDo MljsbY5pcWKrdIOgZ4VtdCCpcn;3eIghfGmvZT3k[ZBmdmSnboTsfS=> Mlr4NlIyODZ{OEK=
LNCaP MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MU[1JI5O NWTJdlBCOjRxNEivO|IhcA>? NF3sdGRqdmirYnn0d{Bk\WyuIHfyc5d1cCC2aX3lMYRmeGWwZHXueIx6 MofyNlIyODZ{OEK=
A549 MlHPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV61JI5O NX6zNpBlOjRxNEivO|IhcA>? M1T4SYlvcGmkaYTzJINmdGxiZ4Lve5RpKHSrbXWt[IVx\W6mZX70cJk> NX\GbYVOOjJzME[yPFI>
697  M3rwT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmXFTWM2OOLCiU5ihKkzNjYEoH7N MoLONlE2Ozh{MU[=
697-R NHTpUZJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2H4U2lEPTEkgJm95qCKQC54wrDuUeKh NVXHSZVDOjF3M{iyNVY>
HUT78 NUjxbVFkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1u0UmlEPTB;MTDuUS=> M4nVRVIyOTl6NUS1
THJ-16T NUPDOWt4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4DVZVEhdk1? NHvFZWYzPCCq MVrpcohq[mm2czDj[YxtKGe{b4f0bC=> M2izRlIxQDFyNU[4
HCT116 MmL2SpVv[3Srb36gRZN{[Xl? M33IPFIxKG6P M2nuXFghcA>? NH7OSFZud2S3bHH0[ZMhfHKjboPjdolxfCCuZY\lcJMh\m:{IHj1coRz\WS|IH;mJIdmdmW|IHnuJIVqfGincjDkbZJm[3Srb36= NVvWUlBzOjB5M{m0OVQ>
B104  MXrGeY5kfGmxbjDBd5NigQ>? M3\oTlIhdk1? MknwNlQwPDhxN{KgbC=> MXXpcoNz\WG|ZYOgeIhmKHO3cn\hZ4Uh\XiycnXzd4lwdiCxZjDDSFIxyqB? M1HLZ|IxPjh4NUC1
HL-60  NWnsUZRnS3m2b4TvfIlkcXS7IFHzd4F6 NF73RocyNTVyMDDuUS=> Ml3oNlQhcA>? MUfpcoR2[2W|IHP5eI91d3irY3n0fUBqdiCjIHPvcoNmdnS{YYTpc44u\GWyZX7k[Y51KG2jbn7lduKh MWCyNFYzPDF4Mx?=
HP100 M{HC[WN6fG:2b4jpZ4l1gSCDc4PhfS=> M1\xe|EuPTByIH7N MUGyOEBp MoPCbY5lfWOnczDjfZRwfG:6aXPpeJkhcW5iYTDjc45k\W62cnH0bY9vNWSncHXu[IVvfCCvYX7u[ZLDqA>? NXOyO2h1OjB4MkSxOlM>
HL-60  NXmwXGtHTnWwY4Tpc44hSXO|YYm= NE\aNIYyOCCwTR?= MkDSOE83NzF4IHi= MnnybY5lfWOnczD0bIUh\2WwZYLheIlwdiCxZjDofYRzd2enbjDw[ZJwgGmmZTDmdo9uKDSq MWGyNFYzPDF4Mx?=
HP100 NEL3[FVHfW6ldHnvckBCe3OjeR?= M3z0R|ExKG6P MoPMOE83NzF4IHi= M4TieYlv\HWlZYOgeIhmKGenbnXyZZRqd25ib3[gbJllem:pZX6gdIVzd3irZHWg[pJwdSB2aB?= NUXXSHJbOjB4MkSxOlM>
HL-60  MlL1SpVv[3Srb36gRZN{[Xl? NYHscmU4OTBvNUCwJI5O NHjZR2c1KGh? M3ezdIRm[3KnYYPld{B1cGViaHnzeI9v\SCmZXHj[ZR6dGG|ZTCoTGRCSyliYXP0bZZqfHoEoB?= M1jPeVIxPjJ2MU[z
HP100 MXnGeY5kfGmxbjDBd5NigQ>? MWCxNE02ODBibl2= MnzwOEBp NFW2[lNl\WO{ZXHz[ZMhfGinIHjpd5RwdmViZHXhZ4V1gWyjc3WgLGhFSUNrIHHjeIl3cXS7wrC= M1PNSFIxPjJ2MU[z
11z NV;ETo9TU2mwYYPlJGF{e2G7 MU[zMVExOCCwTR?= NYjO[mZOemWmdXPld{BJTEGFIHXufplu[XSrYzDhZ5Rqfmm2eTCoTWM2OMLiPTC2MlUhyrFiMD62JI5ud2xxTDm= MX[yNFYxPTF2NB?=
SKOV-3 Mn74S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoLJOE85NzF4IH7N MlTxOFghcA>? M2LySolvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGgZ49v[2WwdILheIlwdi2mZYDlcoRmdnRibXHucoVz MnP6NlA1ODR3NkS=
OVCAR-3 MkfKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWe0M|gwOTZibl2= MoG2OFghcA>? MVTpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHPvcoNmdnS{YYTpc44u\GWyZX7k[Y51KG2jbn7ldi=> NUTRSGo2OjB2MES1OlQ>
HBL-2 NV:0V|Z2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4fYd|IuOTBibl2= NF3tVGUzPCCq MX3JR|UxRTRwMzDuUS=> M3z2ZVIxODZ6MEiw
Jeko-1 NW\UXZhwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVP4WIlLOi13MDDuUS=> MkLwNlQhcA>? NFrMZoRKSzVyPUGxJI5O M1zhfFIxODZ6MEiw
Granta-519 MlfyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX:3NmRIPS12MDDuUS=> M{jGW|I1KGh? NFvq[JdKSzVyPUW4MlUhdk1? NGDhOW8zODB4OEC4NC=>
L1236 MWrDfZRwfG:6aXPpeJkhSXO|YYm= MoqxNUBvVS1zMECg{txO M1LsflQ5KGh? MlW2SWM2OD1yLkC3JO69VQ>? M2LHT|E6OjN|NEew
L428 NW\UdlZ{S3m2b4TvfIlkcXS7IFHzd4F6 Mmj5NUBvVS1zMECg{txO M2Ly[|Q5KGh? NILZZ4ZGSzVyPUCuOFMh|ryP Mm[4NVkzOzN2N{C=
KM-H2 NF7t[ZFEgXSxdH;4bYNqfHliQYPzZZk> NWnlUJU1OSCwTT2xNFAh|ryP NYLvWWh1PDhiaB?= MkPTSWM2OD1yLkW4JO69VQ>? MUexPVI{OzR5MB?=
L540Cy M1XvcmN6fG:2b4jpZ4l1gSCDc4PhfS=> NIDOfIQyKG6PLUGwNEDPxE1? M{jLOlQ5KGh? NVq0SWw{TUN3ME2wMlE3KM7:TR?= M4XuUFE6OjN|NEew
G401 MVfGeY5kfGmxbjDBd5NigQ>? NVLrc2RxOTBibl2= M2T4WVI1NzR6L{eyJIg> NWXDUFM2TE2VTx?= MXfpcoNz\WG|ZYOgR2RMVjGFIHX4dJJme3Orb36= M{jafFE6OjJzNUi2
STM91-01 MoPDSpVv[3Srb36gRZN{[Xl? NYPHfXNNOTBibl2= M2rk[VI1NzR6L{eyJIg> NF7ubFNFVVOR M3Sxe4lv[3KnYYPld{BETEuQMVOg[ZhxemW|c3nvci=> NV:4WnpmOTl{MkG1PFY>
SJSC  NWnnSlB4TnWwY4Tpc44hSXO|YYm= MWSxNEBvVQ>? M13mUVI1NzR6L{eyJIg> MWnEUXNQ MYfpcoNz\WG|ZYOgR2RMVjGFIHX4dJJme3Orb36= MlG4NVkzOjF3OE[=
BT16  NUDSc3VFTnWwY4Tpc44hSXO|YYm= M3;3WFExKG6P NY[3WVB{OjRxNEivO|IhcA>? M{nyTWROW09? M{XweIlv[3KnYYPld{BETEuQMVOg[ZhxemW|c3nvci=> NXm4T3RuOTl{MkG1PFY>
NCI-H1299 M2\tUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVXJR|UxRTRwNtMxNE4zKG6pL33s M4qyOVE6OTd7OEmw
NCI-2882 M2DLSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIPxWXJKSzVyPUGuOuKyOC5yNDDu[{9udA>? M1jV[VE6OTd7OEmw
HCC95 Mn\qS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIWyWJBKSzVyPUKuOeKyOC5yNTDu[{9udA>? M2ruXFE6OTd7OEmw
NCI-H23 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV3JR|UxRTJwOdMxNE4zKG6pL33s NIjkW2IyQTF5OUi5NC=>
NCI-H157 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnLxTWM2OD1zLkdCtVAvODJibnevcYw> M17TUVE6OTd7OEmw
NCI-H460 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4\afWlEPTB;Mj6xxtExNjB5IH7nM41t MYOxPVE4QTh7MB?=
NCI-H1975 NEL5eoNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkXnTWM2OD1zLkRCtVAvODRibnevcYw> NGq1PGsyQTF5OUi5NC=>
NCI-H820 NF3DclNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVHJR|UxRTJwNNMxNE4yKG6pL33s M3nUZ|E6OTd7OEmw
NCI-H1650 NGrST2tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M124emlEPTB;ND65xtExNjNibnevcYw> NEjjVWoyQTF5OUi5NC=>
DTC1 NXTEU3drT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlvNTWM2OD1yLkWxJI5O MVyxPFU3PjJ2Nh?=
KAO MljVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnTETWM2OD1yLkmxJI5O MnjNNVg2PjZ{NE[=
SU-CCS-1 NY\IToJtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3:4RWlEPTB;MD64PUBvVQ>? NGLF[3MyQDV4NkK0Oi=>
SYO-1 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn60TWM2OD1yLk[3JI5O M2nEd|E5PTZ4MkS2
FUJI MofrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4XhUGlEPTB;MT6zNUBvVQ>? NG\wTlUyQDV4NkK0Oi=>
SKNMC NWK0S4lsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX3oOFh7UUN3ME2xMlE4KG6P NEexTZEyQDV4NkK0Oi=>
402-91 MlHPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1rKZWlEPTB;MT6yOkBvVQ>? Mnv3NVg2PjZ{NE[=
1765-92 MoqwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGiyOndKSzVyPUGuO|chdk1? MlTyNVg2PjZ{NE[=
JN-DSRCT-1 NHvjTpZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M17OdGlEPTB;MT6yOUBvVQ>? NUS5UY5QOTh3Nk[yOFY>
NMS-2PC M1j5PWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NETpR45KSzVyPUCuPFEhdk1? NYjLfFU{OTh3Nk[yOFY>
HL60 M1zIU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnjGTWM2OD1zLki2JI5O M3vUXVE5PTZ4MkS2
A549 NGixUlNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX;JR|UxRTNwMkSgcm0> NGXMVHoyQDV4NkK0Oi=>
SW480 NVTtOI1WT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3TIeGlEPTB;Mj62PUBvVQ>? NHvSOJMyQDV4NkK0Oi=>
MCF7 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYHJR|UxRTNwNUWgcm0> MmjNNVg2PjZ{NE[=
PC-3 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml7ZTWM2OD1{LkWxJI5O NWHLXoZIOTh3Nk[yOFY>
MMRU NVPHfGNoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWjp[otEUUN3ME2yMlU4KG6P MW[xPFU3PjJ2Nh?=
Hs68 NUC0cIExT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2\ldGlEPTB;PkGwJI5O M1XMTVE5PTZ4MkS2
hMSC-001F M1u0Umdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2XmN2lEPTB;PkGwJI5O MXGxPFU3PjJ2Nh?=

... Click to View More Cell Line Experimental Data

In vivo Romidepsin treatment potently inhibits the neovascularization of chick embryo and that of adult mice in the Matrigel plug assay. [4]Administration of Romidepsin at 0.1-1 mg/kg twice a week significantly prolongs the survival of mice bearing U-937 lymphoma, with median survival times of 30.5 (0.56 mg/kg) and 33 days (0.32 mg/kg), respectively (vs. 20 days in control mice). [5]

Protocol

Kinase Assay:

[1]

+ Expand

HDAC-inhibitory activity:

For the enzyme assay, 10 μL of [3H]acetyl-labeled histones (25,000 cpm/10 μg) are added to 90 μL of the HDAC enzyme fraction extracted from 293T cells overexpressing HDAC1 or HDAC2 in the presence of increasing concentrations of Romidepsin, and the mixture is incubated at 37 °C for 15 minutes. The enzyme reaction is linear for at least 1 hour. The reaction is stopped by the addition of 10 μL of concentrated HCl. The released [3H]acetic acid is extracted with 1 mL of ethylacetate, and 0.9 mL of the solvent layer is taken into 5 mL of aqueous counting scintillant II solution for determination of radioactivity. The IC50 values are determined from at least three independent dose-response curves.
Cell Research:

[3]

+ Expand
  • Cell lines: HL60, Jurkat, A549, and MCF-7
  • Concentrations: Dissolved in DMSO, final concentrations ~10 μM
  • Incubation Time: 72 hours
  • Method:

    Cells are exposed to various concentrations of Romidepsin for 72 hours in 96-well plates. 20 μL of 5 mg/mL MTT solution in PBS is added to each well for 4 hours. After removal of the medium, 170 μL of DMSO is added to each well to dissolve the formazan crystals. The absorbance at 540 nm is determined. In addition, cells are incubated with trypan blue, and the numbers of blue (dead) cells and transparent (live) cells are counted in a hemocytometer. For cell cycle analysis, cells are incubated for 30 minutes in propidium iodide staining solution containing 0.05 mg/mL propidium iodide, 1 mM EDTA, 0.1% Triton X-100, and 1 mg/mL RNase A in PBS. The suspension is then passed through a nylon mesh filter and analyzed on a Becton Dickinson FACScan.


    (Only for Reference)
Animal Research:

[5]

+ Expand
  • Animal Models: Male scid mice inoculated i.p. with U-937 cells
  • Formulation: Dissolved in DMSO, and diluted in saline
  • Dosages: ~1 mg/kg once or twice a week
  • Administration: Treated i.p.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 10 mg/mL (18.49 mM)
Water <1 mg/mL
Ethanol <1 mg/mL
In vivo 2% DMSO+30% PEG 300+5%Tween 80+ddH2O 5mg/mL

* 1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 540.7
Formula

C24H36N4O6S2

CAS No. 128517-07-7
Storage powder
Synonyms FR 901228, NSC 630176

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT00048334 Completed Neoplasms National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) October 26, 2002 Phase 1
NCT00094978 Terminated Carcinoma, Small Cell|Carcinoma, Non-Small-Cell Lung|Esophageal Neoplasms|Mesothelioma National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) October 25, 2004 Phase 1
NCT01445340 Terminated Mycosis Fungoides|Cutaneous T-Cell Lymphoma|Neoplasms National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) April 21, 2007 Phase 1
NCT02616965 Not yet recruiting Cutaneous T-cell Lymphoma (CTCL) Fox Chase Cancer Center|Seattle Genetics, Inc.|Celgene Corporation April 2017 Phase 1
NCT02850016 Recruiting Human Immunodeficiency Virus (HIV) Rockefeller University|University Hospital of Cologne|Aarhus University Hospital December 2016 Phase 2
NCT02757248 Withdrawn PTCL|CTCL Anne Beaven, MD|National Comprehensive Cancer Network|Boehringer Ingelheim|Duke University November 2016 Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

HDAC Signaling Pathway Map

HDAC Inhibitors with Unique Features

Related HDAC Products

Tags: buy Romidepsin (FK228, Depsipeptide) | Romidepsin (FK228, Depsipeptide) supplier | purchase Romidepsin (FK228, Depsipeptide) | Romidepsin (FK228, Depsipeptide) cost | Romidepsin (FK228, Depsipeptide) manufacturer | order Romidepsin (FK228, Depsipeptide) | Romidepsin (FK228, Depsipeptide) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID